Conferences
AAPS 2025 PHarmSCi 360
-
November 9-12, 2025
-
San Antonio, Texas, US
We look forward to seeing you at the 2025 PharmSci 360 held on November 9-12, 2025 in San Antonio, Texas!
AAPS is the convener of the pharmaceutical science community, bringing together thousands of scientists from across the world and the drug development process. For them, PharmSci 360 combines all the energy of a large scientific conference with the intimacy of a small niche meeting because of its unique programming structure.
PharmSci 360 is built on five tracks that cover the pharmaceutical development process. Scientists attending the meeting report that they build their schedule to solve their problems, and may attend programming in only one track or all of them!
Featured Presentations
Bridging In Vitro to In Vivo: Preclinical In Vitro Models for Characterizing
Hong Zhang, Ph.D.
Learning Objective:
Upon completion, participants will be able to understand the importance of in vitro metabolic stability screening and the relevant experimental systems for oligonucleotide drug development.
Upon completion, participants will be able to describe limitations of current in vitro models and apply strategies to select suitable systems for oligonucleotide metabolic stability assessment and metabolite identification.
Upon completion, participants will be able to understand strategies for oligonucleotide metabolite identification.
Oral Peptide Drug Development: Addressing Preclinical Bioavailability and PK Challenges
Jianping Sun
Learning Objective:
Upon completion, participants will be able to identify key bioavailability and pharmacokinetic barriers in preclinical peptide drug development.
Upon completion, participants will be able to explore practical strategies to optimize DMPK properties of peptide therapeutics.
Upon completion, participants will be able to enhance their understanding of assay selection, sample processing, and study design tailored to peptides.
Speakers
Our posters
Other Resources
-
Our posters -
Other Resources
-
-
Human Pharmacokinetics Prediction for Trastuzumab Using Scaling and Two-Compartment Modeling with B-hFcRn Mice PK Data
Biocytogen humanized neonatal Fc receptor mice (B-hFcRn mice) offer an alternative model for Tg32 mice in pharmacokinetic studies of biologics; however, differences between B-hFcRn and Tg32 mice raise uncertainties about whether data from B-hFcRn mice can reliably predict human pharmacokinetics.
-
Development and Implementation of a Ferret Venous Catheterization Model for Pharmacokinetic Studies
The ferret (Mustela putorius furo) is an indispensable experimental animal model in the fields of influenza virology, respiratory diseases, and vaccine development. However, its unique physiological and anatomical characteristics pose significant challenges for venous blood sampling. The peripheral blood vessels, such as the saphenous and caudal veins, are extremely narrow (0.3-0.5mm in diameter), and the subcutaneous fat layer combined with thick epidermal structures complicates visualization. Additionally, ferrets exhibit a more pronounced stress-induced vascular contraction response compared to rodents, resulting in a lower success rate of traditional blood sampling.
-
Enhancing Oral Bioavailability in Preclinical Dog PK Studies Using Ball Milling Technology
Ball milling technology has the potential to enhance the oral bioavailability of poorly soluble drugs by reducing particle size, which can lead to improved systemic exposure in vivo. For heat-sensitive drugs, it is important to use intermittent milling and controlled speed to prevent degradation. We have evaluated a series of dispersants to ensure stability and proper particle size for nanometer suspension. Selecting the appropriate stabilizer and carefully considering critical instrument parameters are crucial steps in preparing effective nanometer suspensions. In summary, the careful selection of dispersants and the optimization of milling parameters are essential for preparing high-performance nanometer suspensions.
-
Application of Lecithin (PL90) and Poloxamer 188 in SLC Transporter-Mediated Drug Interaction Studies
Solute Carrier (SLC) transporter-mediated drug interaction studies are essential in drug development. However, poor solubility and/or non-specific binding issues of highly lipophilic compounds pose significant challenges in in vitro research. Pharmaceutical excipients such as lecithin (PL90) and poloxamer 188 can improve solubility and/or reduce non-specific binding of highly lipophilic compounds. This study aimed to evaluate the effects of PL90 and poloxamer 188 on SLC transporter activities and to establish a good method for assessing transporter-mediated drug interaction studies of highly lipophilic compounds.
-
Integrated High-Throughput Platform for Covalent Inhibitor Screening and Characterization
In this work, we have established a high-throughput screening and characterization platform based on DSF, intact protein and peptide mapping analysis, which applies to covalent inhibitors. The platforms show high-throughput, accuracy, stability, and rapidity.
-
Sensitive LC-MS/MS Method for Cationic Ligand-Conjugated siRNA Therapeutics
To address the issue of low mass spectrometry response, ammonia solution was added to the plasma matrix to replace ammonium acetate buffer. The introduction of NH3·H2O leads to the deprotonation of amine groups on the ligand (NH2+ → -NH), reducing their positive charge and weakening their interaction with the matrix, thus preventing co-precipitation with the matrix. At the same time, the increase in OH results in the deprotonation of the siRNA phosphate backbone (-PO4H- → -PO42-), increasing its negative charge and enhancing hydrophilicity, which favors retention in the aqueous phase and improves extraction efficiency.
View More -
-
-
Evaluation of Clearance Prediction Methods for Vepdegestrant (ARV-471) Using PBPK Modelling: Insights into PROTAC Clinical Pharmacokinetics
PostersSep 11,2025
-
Bioanalytical Strategy for Antibody-Drug Conjugates (ADCs) Based on Integrated Mass Spectrometry Bioanalysis Platform
PostersSep 11,2025 -
Evaluating Oral Peptides' Gastrointestinal Absorption: Methods and Applications
ArticlesAug 28,2025
-
Related Services and Platforms
Stay Connected
Keep up with the latest news and insights.
